EGFR and neoplasm: We observed that the two PDECX models with EGFR gene amplification (PDECX1T0326 and PDECX1T0950) were most sensitive to theliatinib treatment demonstrating tumor regression of 32% and 75%, respectively, at the end of study (Figure 4 and Table 4).